相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
David Devos et al.
ANTIOXIDANTS & REDOX SIGNALING (2014)
6-Hydroxydopamine promotes iron traffic in primary cultured astrocytes
Hao-Yun Zhang et al.
BIOMETALS (2013)
Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators
Orly Weinreb et al.
FREE RADICAL BIOLOGY AND MEDICINE (2013)
Hydroxypyridinones as privileged chelating structures for the design of medicinal drugs
M. Amelia Santos et al.
COORDINATION CHEMISTRY REVIEWS (2012)
Design of iron chelators with therapeutic application
Tao Zhou et al.
DALTON TRANSACTIONS (2012)
Different 8-Hydroxyquinolines Protect Models of TDP-43 Protein, α-Synuclein, and Polyglutamine Proteotoxicity through Distinct Mechanisms
Daniel F. Tardiff et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease
Alessandra Gaeta et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration
David T. Dexter et al.
JOURNAL OF NEURAL TRANSMISSION (2011)
The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity
Peter J. Crouch et al.
JOURNAL OF NEUROCHEMISTRY (2011)
Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease
C. B. Carroll et al.
NEUROCHEMISTRY INTERNATIONAL (2011)
The potential application of iron chelators for the treatment of neurodegenerative diseases
Robert C. Hider et al.
METALLOMICS (2011)
Metal Ionophore Treatment Restores Dendritic Spine Density and Synaptic Protein Levels in a Mouse Model of Alzheimer's Disease
Paul A. Adlard et al.
PLOS ONE (2011)
The emergence of designed multiple ligands for neurodegenerative disorders
Werner J. Geldenhuys et al.
PROGRESS IN NEUROBIOLOGY (2011)
Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson's and Alzheimer's Diseases as Disease Modifying Agents
Moussa B. H. Youdim
Experimental Neurobiology (2011)
Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent
Hong Jiang et al.
CELL RESEARCH (2010)
Reconstruction and quantitative evaluation of dopaminergic innervation of striatal neurons in dissociated primary cultures
Seiko Wakita et al.
JOURNAL OF NEUROSCIENCE METHODS (2010)
Chemistry and biology of siderophores
Robert C. Hider et al.
NATURAL PRODUCT REPORTS (2010)
A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease
Pier Giorgio Mastroberardino et al.
NEUROBIOLOGY OF DISEASE (2009)
Chelation Therapy for Neurodegenerative Diseases
Silvia Bolognin et al.
MEDICINAL RESEARCH REVIEWS (2009)
Iron trafficking inside the brain
Torben Moos et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: Implications for idiopathic and monogenetic forms
Daniela Berg
NEUROCHEMICAL RESEARCH (2007)
Variable C-2-symmetric analogues of N-hydroxyphthalimide as enantioselective catalysts for aerobic oxidation: Kinetic resolution of oxazolidines
Malek Nechab et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2007)
Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences
Hava Glickstein et al.
BLOOD (2006)
Cymothoe sangaris:: An extremely stable and highly luminescent 1,2-hydroxypyridinonate chelate of Eu(III)
Evan G. Moore et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2006)
Bis(oxazoline) Lewis acid catalyzed aldol reactions of pyridine N-oxide aldehydes -: Synthesis of optically active 2-(1-hydroxyalkyl)pyridine derivatives:: Development, scope, and total synthesis of an indolizine alkaloid
A Landa et al.
CHEMISTRY-A EUROPEAN JOURNAL (2006)
The evolution of iron chelators for the treatment of iron overload disease and cancer
DS Kalinowski et al.
PHARMACOLOGICAL REVIEWS (2005)
Gadolinium(III) 1,2-hydroxypyridonate-based complexes: Toward MRI contrast agents of high relaxivity
J Xu et al.
INORGANIC CHEMISTRY (2004)
Emerging understanding of the advantage of small molecules such as hydroxypyridinones in the treatment of iron overload
RC Hider et al.
CURRENT MEDICINAL CHEMISTRY (2003)
Rational design of sequestering agents for plutonium and other actinides
AEV Gorden et al.
CHEMICAL REVIEWS (2003)
The labile iron pool: Characterization, measurement, and participation in cellular processes
O Kakhlon et al.
FREE RADICAL BIOLOGY AND MEDICINE (2002)
Design of iron chelators with therapeutic application
ZD Liu et al.
COORDINATION CHEMISTRY REVIEWS (2002)
Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease
BA Faucheux et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Synthesis and initial evaluation for in vivo chelation of Pu(IV) of a mixed octadentate spermine-based ligand containing 4-carbamoyl-3-hydroxy-1-methyl-2(1H)-pyridinone and 6-carbamoyl-1-hydroxy-2(1H)-pyridinone
J Xu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Brain iron pathways and their relevance to Parkinson's disease
D Berg et al.
JOURNAL OF NEUROCHEMISTRY (2001)
Structure-activity investigation of the inhibition of 3-hydroxypyridin-4-ones on mammalian tyrosine hydroxylase
ZD Liu et al.
BIOCHEMICAL PHARMACOLOGY (2001)
Synthesis of 3,4,3 LI 1,2 HOPO labelled with C-14.
R Burgada et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2001)
Fast biological iron chelators: kinetics of iron removal from human diferric transferrin by multidentate hydroxypyridonates
I Turcot et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2000)
Sequestration of iron by Lewy bodies in Parkinson's disease
RJ Castellani et al.
ACTA NEUROPATHOLOGICA (2000)
分享论文
